Biomea Fusion (BMEA)
NASDAQ:BMEA
Want to see BMEA full AI Analyst Report?
Top Page
Biomea Fusion
(NASDAQ:BMEA)
Select Model
Select Model
Rating:48Neutral
Price Target:
$1.50
▼(-32.13% Downside)
Action:Reiterated
Date:05/14/26
The score is primarily held back by weak financial fundamentals (no revenue, ongoing losses and cash burn, and a shrinking equity base), with additional pressure from negative/soft technical momentum. Offsetting this, recent corporate updates include encouraging Phase 2 T1D data and clear next-study plans, supporting a higher outlook than the financials alone would imply.
Positive Factors
Differentiated R&D platform
Biomea's focus on covalent small-molecule design aims for durable target engagement versus reversible agents. That scientific differentiation can provide sustained pharmacology, a harder-to-replicate mechanism and a platform advantage that supports pipeline value and partnerships across multiple indications over 2-6 months.
Negative Factors
No product revenue
As a clinical-stage company with zero product revenue, Biomea relies on external financing or partnerships to fund operations. Lack of recurring income creates persistent funding dependency, increasing execution risk and the potential for program delays or scope reductions absent new capital.
Read all positive and negative factors
Positive Factors
Negative Factors
Differentiated R&D platform
Biomea's focus on covalent small-molecule design aims for durable target engagement versus reversible agents. That scientific differentiation can provide sustained pharmacology, a harder-to-replicate mechanism and a platform advantage that supports pipeline value and partnerships across multiple indications over 2-6 months.
Read all positive factors
Biomea Fusion (BMEA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$91.82M
Dividend YieldN/A
Average Volume (3M)2.40M
Price to Earnings (P/E)―
Beta (1Y)1.84
Revenue GrowthN/A
EPS Growth74.83%
CountryUS
Employees79
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.89
Shares Outstanding72,299,440
10 Day Avg. Volume5,869,688
30 Day Avg. Volume2,395,415
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)2.19
Price to Sales (P/S)0.00
P/FCF Ratio-0.92
Enterprise Value/Market Cap0.42
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-65.18
Enterprise Value/Ebitda-0.62
Forecast
1Y Price Target
$7.20Price Target Upside225.79% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)-0.82
Revenue Forecast (FY)N/A
Biomea Fusion Business Overview & Revenue Model
Company Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally...
How the Company Makes Money
Biomea Fusion’s revenue model is primarily based on (1) collaboration and licensing arrangements, if and when in place, and (2) financing activities (e.g., equity offerings) used to fund operations while products are in development. As a clinical-...
Biomea Fusion Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
50
Neutral
Cash Flow
22
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -593.00K | -1.41M | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -62.81M | -79.90M | -142.32M | -124.62M | -82.94M | -41.42M |
| Net Income | -44.95M | -61.80M | -138.43M | -117.25M | -81.83M | -41.57M |
Balance Sheet | ||||||
| Total Assets | 46.38M | 58.57M | 79.94M | 199.93M | 129.31M | 185.71M |
| Cash, Cash Equivalents and Short-Term Investments | 44.69M | 55.81M | 58.28M | 176.87M | 113.05M | 173.52M |
| Total Debt | 1.24M | 1.59M | 8.77M | 10.30M | 2.29M | 2.85M |
| Total Liabilities | 27.67M | 29.02M | 28.36M | 30.69M | 20.77M | 6.92M |
| Stockholders Equity | 18.72M | 29.55M | 51.57M | 169.24M | 108.54M | 178.78M |
Cash Flow | ||||||
| Free Cash Flow | -56.25M | -70.37M | -120.26M | -99.96M | -63.45M | -38.61M |
| Operating Cash Flow | -56.25M | -70.37M | -119.89M | -96.59M | -62.42M | -35.44M |
| Investing Cash Flow | 550.00K | 0.00 | -362.00K | -2.22M | 27.34M | -33.35M |
| Financing Cash Flow | 64.53M | 67.90M | 1.67M | 163.80M | 1.24M | 153.19M |
Biomea Fusion Technical Analysis
Negative
2.21
Price Trends
1.57
Negative
1.44
Negative
1.49
Negative
Market Momentum
-0.06
Negative
39.58
Neutral
16.73
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BMEA, the sentiment is Negative. The current price of 2.21 is above the 20-day moving average (MA) of 1.39, above the 50-day MA of 1.57, and above the 200-day MA of 1.49, indicating a bearish trend. The MACD of -0.06 indicates Negative momentum. The RSI at 39.58 is Neutral, neither overbought nor oversold. The STOCH value of 16.73 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BMEA.
Biomea Fusion Risk Analysis
Biomea Fusion disclosed 91 risk factors in its most recent earnings report. Biomea Fusion reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Biomea Fusion Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $91.82M | -2.04 | -196.72% | ― | ― | 74.83% | |
48 Neutral | $134.51M | 1.90 | -23.05% | ― | 24.46% | ― | |
48 Neutral | $38.49M | -1.02 | -84.91% | ― | ― | -40.23% | |
48 Neutral | $447.94M | -7.32 | -22.51% | ― | 1199.64% | 30.81% | |
47 Neutral | $88.03M | -8.71 | -666.47% | ― | -100.00% | 46.40% | |
46 Neutral | $99.02M | -1.42 | -26.58% | ― | -1.44% | 11.50% |
* Healthcare Sector Average
BMEA
Biomea Fusion
1.27
-1.36
-51.71%
AGEN
Agenus
3.23
-2.32
-41.80%
INO
Inovio Pharmaceuticals
1.07
-1.15
-51.80%
ATOS
Atossa Therapeutics
4.47
-9.24
-67.40%
OVID
Ovid Therapeutics
2.40
2.07
625.08%
SEER
Seer
1.79
-0.41
-18.64%
Biomea Fusion Corporate Events
Business Operations and Strategy
Biomea Fusion Reports Positive Phase 2 T1D Trial Results
Positive
Apr 28, 2026
On April 27, 2026, Biomea Fusion reported positive 52-week results from its Phase 2 COVALENT-112 trial of icovamenib in adults with Stage 3 type 1 diabetes, showing substantial and durable preservation of beta cell function after only 12 weeks of ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.